New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Seres Therapeutics, Inc. (MCRB) vs Pluri Inc. (PLUR)
- Seres Therapeutics, Inc. MCRB 1.24 −6.77%
- Pluri Inc. PLUR 0.94 −3.09%
Seres Therapeutics, Inc. and Pluri Inc. are both Biotechnology companies. Seres Therapeutics, Inc. and Pluri Inc. are of similar size ($13.9M and $13.6M). Pluri Inc. has the higher net margin (−1,943.9% vs −2,209.6%) and the higher return on invested capital (−436.8% vs −1,267.8%). Across the 13 metrics below, Pluri Inc. leads on 8 and Seres Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | MCRB | PLUR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 51.95% | 70.18% |
| Operating margin | (3,656.89%) | (2,341.12%) | 0.00% |
| Net margin | (2,209.55%) | (1,943.87%) | 0.00% |
| Free cash flow margin | — | (1,316.52%) | 0.00% |
| Return on equity | (144.35%) | 253.49% | (51.58%) |
| Return on assets | (44.85%) | (96.79%) | (45.91%) |
| Return on invested capital | (1,267.77%) | (436.83%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack